Literature DB >> 26739465

[The guideline of prevention and treatment for hepatitis C: a 2015 update].

Lai Wei1, Jin-Lin Hou2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26739465     DOI： 10.3760/cma.j.issn.1007-3418.2015.12.003

Source DB:  PubMed          Journal:  Zhonghua Gan Zang Bing Za Zhi        ISSN： 1007-3418


× No keyword cloud information.
  36 in total

1.  KIR2DL2/C1 is a Risk Factor for Chronic Infection and Associated with Non-response to PEG-IFN and RBV Combination Therapy in Hepatitis C Virus Genotype 1b Patients in China.

Authors:  Song Hu; Fahu Yuan; Lingyan Feng; Fang Zheng; Feili Gong; Hanju Huang; Binlian Sun
Journal:  Virol Sin       Date:  2018-07-23       Impact factor: 4.327

Review 2.  Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.

Authors:  Shiv K Sarin; Manoj Kumar; Mohammed Eslam; Jacob George; Mamun Al Mahtab; Sheikh M Fazle Akbar; Jidong Jia; Qiuju Tian; Rakesh Aggarwal; David H Muljono; Masao Omata; Yoshihiko Ooka; Kwang-Hyub Han; Hye Won Lee; Wasim Jafri; Amna S Butt; Chern H Chong; Seng G Lim; Raoh-Fang Pwu; Ding-Shinn Chen
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-12-15

3.  Plasma Golgi protein 73 levels predict prognosis of HCV-related hepatic fibrosis.

Authors:  Lingdi Liu; Zaid Al-Dhamin; Xiwei Yuan; Luyao Cui; Yang Yang; Wen Zhao; Ying Zhang; Na Fu; Yuemin Nan
Journal:  Histol Histopathol       Date:  2020-10-14       Impact factor: 2.303

4.  Chinese guidelines on the management of ascites and its related complications in cirrhosis.

Authors:  Xiaoyuan Xu; Zhongping Duan; Huiguo Ding; Wengang Li; Jidong Jia; Lai Wei; Enqiang Linghu; Hui Zhuang
Journal:  Hepatol Int       Date:  2019-01-18       Impact factor: 6.047

5.  HCV inhibits M2a, M2b and M2c macrophage polarization via HCV core protein engagement with Toll-like receptor 2.

Authors:  Shixing Zhao; Meng Si; Xianpei Deng; Dengqin Wang; Lingbin Kong; Qianqian Zhang
Journal:  Exp Ther Med       Date:  2022-06-16       Impact factor: 2.751

6.  Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients.

Authors:  Dong Ji; Guo-Feng Chen; Cheng Wang; Yu-Dong Wang; Qing Shao; Bing Li; Jun Zhao; Shao-Li You; Jin-Hua Hu; Jia-Liang Liu; Xiao-Xia Niu; Jing Chen; Lei Lu; Vanessa Wu; George Lau
Journal:  Hepatol Int       Date:  2016-07-21       Impact factor: 6.047

Review 7.  Shifting Epidemiology of Hepatocellular Carcinoma in Far Eastern and Southeast Asian Patients: Explanations and Implications.

Authors:  Nguyen H Tran
Journal:  Curr Oncol Rep       Date:  2022-01-21       Impact factor: 5.075

8.  Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens.

Authors:  Jianhong Chen; Xiaxia Zhang; Hao Luo; Chihong Wu; Min Yu; Dan Liu; Hongli Xi; Yihang Zhou; Yaoyu An; Xiaoyuan Xu
Journal:  Oncotarget       Date:  2017-06-28

9.  Involvement of the Interleukin-23/Interleukin-17 Axis in Chronic Hepatitis C Virus Infection and Its Treatment Responses.

Authors:  Ping Meng; Suxian Zhao; Xuemin Niu; Na Fu; Shanshan Su; Rongqi Wang; Yuguo Zhang; Liang Qiao; Yuemin Nan
Journal:  Int J Mol Sci       Date:  2016-07-15       Impact factor: 5.923

10.  Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.

Authors:  Carlo Smirne; Antonio D'Avolio; Mattia Bellan; Alessandro Gualerzi; Maria G Crobu; Mario Pirisi
Journal:  Pharmacol Res Perspect       Date:  2021-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.